Abstract:Lung adenocarcinoma was diagnosed in a 57-year-old female never-smoker with a subpleural mass in right upper lobe and enlarged mediastinal lymph nodes. Targeted next-generation sequencing for 425 cancer-related genes was performed to evaluate the oncogenes at the primary site, and EGFR exon 20 insertion mutation (p.H773dup) was shown. Unfortunately, she progressed with brain metastasis, accompanied by pericardial effusion and an enlarged right supraclavicular lymph node despite definitive chemoradiotherapy. She benefitted from subsequent treatment with six cycles of pemetrexed-cisplatin combined with bevacizumab. Local progression at the primary site occurred right after two additional cycles of maintenance therapy. The patient received radiation for the primary site; however, repeat imaging 1 month later revealed multiple bilateral lung metastases. Third-line therapy using nivolumab was given, and the patient reported severe dry cough along with left lower abdominal pain after 6 weeks of treatment. She progressed with multiple lung, brain, liver, and omentum metastasis and an enlarged retroperitoneal lymph node (Fig. 1). Suspicious hyperprogressive disease (HPD) developed. Rebiopsy of the omentum lesion was conducted and the pathological analysis indicated NSCLC, not otherwise specified. In addition to the EGFR exon 20 insertion mutation, EGFR and v-myc avian myelocytomatosis viral oncogene homolog gene (MYC) amplification were observed in reassessment of the mutation profiling. Although albumin paclitaxel and apatinib, a highly selective vascular endothelial growth factor receptor 2 inhibitor, were administered, the patient still died of rapid systematic progression afterward. HPD is a paradoxical pattern of tumor progression with a disputed definition.1Lo Russo G. Moro M. Sommariva M. et al.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade.Clin Cancer Res. 2019; 25: 989-999Crossref PubMed Scopus (256) Google Scholar, 2Kato S. Goodman A. Walavalkar V. Barkauskas D.A. Sharabi A. Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (580) Google Scholar, 3Ferrara R. Mezquita L. Texier M. et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.JAMA Oncol. 2018; 4: 1543-1552Crossref PubMed Scopus (464) Google Scholar The rate of occurrence of HPD in NSCLC ranges from 8% to 21%, and it is usually accompanied by extremely poor outcome, with the median overall survival being only 3 months. Questions of mechanism notwithstanding, it is reasonable to assume that immune checkpoint inhibitors (ICIs) might break the homeostatic state between the elimination and escape phases of cancer immunoediting, facilitating immune escape and accelerated tumor growth.4Champiat S. Ferrara R. Massard C. et al.Hyperprogressive disease: recognizing a novel pattern to improve patient management.Nat Rev Clin Oncol. 2018; 15: 748-762Crossref PubMed Scopus (247) Google Scholar Older age and high metastatic burden before immunotherapy are associated with HPD.3Ferrara R. Mezquita L. Texier M. et al.Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy.JAMA Oncol. 2018; 4: 1543-1552Crossref PubMed Scopus (464) Google Scholar In addition, MDM2 proto-oncogene gene (MDM2)/MDM4 regulator of p53 gene (MDM4) amplification, EGFR E746_A750del and T790M mutation, and gene amplification on the chromosome 11q13 are significantly correlated with HPD.2Kato S. Goodman A. Walavalkar V. Barkauskas D.A. Sharabi A. Kurzrock R. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate.Clin Cancer Res. 2017; 23: 4242-4250Crossref PubMed Scopus (580) Google Scholar The accumulated evidence indicates that EGFR-mutated tumors usually predict a less satisfactory rate of response to ICIs. EGFR exon 20 insertion is the most common atypical EGFR mutation (4%–9.2%) and is known to confer resistance to current clinically available EGFR tyrosine kinase inhibitors. The relationship between EGFR exon 20 insertion and ICI-induced HPD is unknown. Our case is the first to report that nivolumab triggered HPD, leading to rapid death in a patient having EGFR exon 20 insertion mutation and MYC amplification. A very recent study provided direct evidence that treatment with nivolumab boosted EGFR-mutated tumor growth through interaction with M2-like macrophages.1Lo Russo G. Moro M. Sommariva M. et al.Antibody-Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non-small cell lung cancer subsequent to PD-1/PD-L1 blockade.Clin Cancer Res. 2019; 25: 989-999Crossref PubMed Scopus (256) Google Scholar The emerging MYC amplification that was demonstrated in our patient was also suggested to contribute to tumor growth by upregulating CD47 molecule and programmed death ligand 1 expression.5Casey S.C. Tong L. Li Y. et al.MYC regulates the antitumor immune response through CD47 and PD-L1.Science. 2016; 352: 227-231Crossref PubMed Scopus (750) Google Scholar In addition, using the Kyoto Encyclopedia of Genes and Genomes and Gene Ontology database, we analyzed the mutation profiles before and after ICI administration. No other immune-related signaling pathway was involved. In this regard, EGFR aberrations and MYC amplification are considered as the potential mechanism explaining why HPD developed in our case. Administration of ICI monotherapy in this subgroup of patients must be performed with caution. This work was supported by the National Natural Science Foundation of China (grant 81870022) and the Medical and Health Technology Program of Zhejiang Province (grant 2017204226) to Dr. Xia.

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy

Hyperprogression after pembrolizumab treatment in two patients with metastatic urothelial carcinoma

Hyperprogression after Immunotherapy in Patients with Malignant Tumors of Digestive System

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer

Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature

Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification

Pseudoprogression of thoracic tumor after radiotherapy in the era of immunotherapy: a case series

Life-threatening "hyper-progression" on immunotherapy revealed as pseudo-progression in DNA mismatch repair deficiency: a case report

Redefining Clinical Hyperprogression: the Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy

Abstract 3548: Role of the cancer cell proteome and tumor microenvironment in the hyperprogression (HP) phenotype response to immune checkpoint blockade

Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition

Hyperprogressive Disease: Main Features and Key Controversies

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy

The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

Hyperprogressive disease in patients with advanced cancer treated with immune checkpoint inhibitors

Pseudoprogression during induction treatment with nivolumab plus ipilimumab combined with chemotherapy for metastatic lung adenocarcinoma: A case report

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors

Excellent Response to Atezolizumab After Clinically Defined Hyperprogression Upon Previous Treatment With Pembrolizumab in Metastatic Triple-Negative Breast Cancer: A Case Report and Review of the Literature

Case Report: Tumor Microenvironment Characteristics in a Patient with HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease.